These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17921029)

  • 1. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
    Zalutsky MR; Reardon DA; Pozzi OR; Vaidyanathan G; Bigner DD
    Nucl Med Biol; 2007 Oct; 34(7):779-85. PubMed ID: 17921029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
    Vaidyanathan G; Zalutsky MR
    Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
    Zalutsky MR; Vaidyanathan G
    Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy using alpha emitters.
    Vaidyanathan G; Zalutsky MR
    Phys Med Biol; 1996 Oct; 41(10):1915-31. PubMed ID: 8912371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
    Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
    J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astatine-211: production and availability.
    Zalutsky MR; Pruszynski M
    Curr Radiopharm; 2011 Jul; 4(3):177-85. PubMed ID: 22201707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
    Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
    Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and perspectives in alpha radioimmunotherapy.
    Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
    Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
    Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
    McLendon RE; Archer GE; Larsen RH; Akabani G; Bigner DD; Zalutsky MR
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):491-9. PubMed ID: 10487576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
    Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
    Larsen RH; Bruland OS; Hoff P; Alstad J; Lindmo T; Rofstad EK
    Radiat Res; 1994 Aug; 139(2):178-84. PubMed ID: 8052693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astatine-211: its possible applications in cancer therapy.
    Brown I
    Int J Rad Appl Instrum A; 1986; 37(8):789-98. PubMed ID: 3021680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy.
    Humm JL
    Int J Radiat Oncol Biol Phys; 1987 Nov; 13(11):1767-73. PubMed ID: 3667382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.